The Diopsys NOVA-DN allows clinicians to objectively assess optic nerve disease earlier than traditional vision tests as it uses Visual Evoked Potential (VEP) technology and proprietary software to evaluate the entire vision system from the eye to the visual cortex.

Diopsys neuro-ophthalmologist and research director Alberto Gonzalez Garcia said VEP is an objective, functional test that can help discriminate between healthy and glaucomatous eyes.

Optometrists and ophthalmologists may use VEP in addition to traditional testing methods to enhance diagnosis and treatment.

The Diopsys NOVA-DN records the electrical response of a patient’s entire vision system and provides easy-to-read reports that give the doctor a simple way to evaluate optic nerve function.

Physicians are able to compare tests over time to track disease progression.